Kiniksa Pharmaceuticals International, plc

Kiniksa reported Q2 2026 ARCALYST net revenue of $243.6 million, up 55% year over year and more than $85 million above Q2 2025 and more than $29 million above Q1 2026. Operating income was $27.2 million and net income was $25.4 million, while collaboration profit increased 68% year over year to $176.1 million. The company ended the quarter with $525.9 million in cash and approximately $58 million of net cash generation. Management raised full-year 2026 revenue guidance to $980 million-$995 million from $930 million-$945 million.

Sanj Patel said Kiniksa is in a strong position more than halfway through 2026, citing commercial momentum, pipeline progress, and a strong balance sheet. He emphasized that ARCALYST execution, the initiation of the Phase III KPL-387 program, and the planned start of KPL-1161 Phase I by year-end create multiple near- and long-term value drivers. His tone was upbeat and confident, but he repeatedly framed growth as the result of disciplined execution rather than a one-time event.

Mark Ragosa highlighted that ARCALYST revenue grew 55% year over year to $243.6 million, with operating income of $27.2 million and net income of $25.4 million. He said collaboration profit rose 68% year over year to $176.1 million, helped by disciplined commercial investment. He also noted the company ended Q2 with $525.9 million in cash and generated about $58 million of net cash in the period, while gross-to-net was 7.2% year to date, down from 8.6% in Q1 because of lower copay support.

Analysts focused on what drove the sharp ARCALYST acceleration, whether it can continue, and whether the first-recurrence population is contributing meaningfully. Management pointed to more than 450 new prescribers, more than 150 additional repeat prescribers, better market understanding, the DTC campaign, AI- and machine-learning-enabled targeting, and broader adoption of the ACC concise clinical guidance. On KPL-387, management said the Phase II data were consistent with prior IL-1 inhibition results, that the 300 mg monthly dose was selected for Phase III, and that market research suggested a monthly profile could be attractive, with about 75% of patients and 92% of health care professionals expressing favorable views.